Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Torsemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 10/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | BRS3 | P32247 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torsemide SCHEMBL41184 | 0.96 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL29395363 | 0.96 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL29369134 | 0.96 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL4015063 | 0.96 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL6315139 | 0.95 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL6307778 | 0.95 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL4838293 | 0.95 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL28460508 | 0.95 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL4827506 | 0.95 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL22687888 | 0.94 | TBXA2R (0.96) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070260068-A1 | Method for the Preparation of Crystal Forms of Torsemide in a Pure State | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2007-11-08 | — | — | US | claimed |
| EP-1207880-A4 | TORSEMIDE POLYMORPHS | TEVA PHARMA (IL) | 2004-09-01 | — | — | EP | claimed |
| US-6465496-B1 | DUPONT FORM 2 ETHANOL AND ISOPROPANOL ADDUCTS; SUSPENDING TORSEMIDE IN WATER, BASIFYING, ADDING ORGANIC SOLVENT, ACID PRECIPITATING AND ISOLATING ADDUCT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2002-10-15 | — | — | US | claimed |
| EP-1207880-A1 | TORSEMIDE POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-05-29 | — | — | EP | claimed |
| WO-2001010441-A1 | TORSEMIDE POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-02-15 | — | — | WO | claimed |
| US-20070260068-A1 | Method for the Preparation of Crystal Forms of Torsemide in a Pure State | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2007-11-08 | — | — | US | disclosed |
| EP-1207880-A4 | TORSEMIDE POLYMORPHS | TEVA PHARMA (IL) | 2004-09-01 | — | — | EP | disclosed |
| US-6465496-B1 | DUPONT FORM 2 ETHANOL AND ISOPROPANOL ADDUCTS; SUSPENDING TORSEMIDE IN WATER, BASIFYING, ADDING ORGANIC SOLVENT, ACID PRECIPITATING AND ISOLATING ADDUCT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2002-10-15 | — | — | US | disclosed |
| EP-1207880-A1 | TORSEMIDE POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001010441-A1 | TORSEMIDE POLYMORPHS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260068-A1 | Method for the Preparation of Crystal Forms of Torsemide in a Pure State | TOR1AIP1, ADH1C, RAP2C | TBXA2R 787/4885KDM4E 3204/4885CYP3A4 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.